Trial Profile

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elacestrant (Primary) ; Anastrozole; Exemestane; Letrozole; Tamoxifen
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms TREAT ctDNA

Most Recent Events

19 Aug 2025 Planned End Date changed from 1 May 2030 to 1 Nov 2035.
19 Aug 2025 Planned primary completion date changed from 1 Jul 2028 to 1 Nov 2032.
22 May 2025 According to a Menarini media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com